Search research articles
Contact Us
Filters
Showing results (641-650 of 762) with videos related to
Page
of 77
Sort By:
Annals of Surgical Oncology
|
June 29, 2007
Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit
Katrina H Moore, Karl J Sweeney, Meaghan E Wilson, et al.
The Lancet. Oncology
|
January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Claire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
BJU International
|
April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancer
Kathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 25, 2005
Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13
Mark C Noe, Vijayalakshmi Natarajan, Sheri L Snow, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 3, 2003
Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors
Michael A Letavic, John T Barberia, Thomas J Carty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
Lauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
The Journal of Urology
|
July 27, 2011
Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer
Peter Chang, Konrad M Szymanski, Rodney L Dunn, et al.
The New England Journal of Medicine
|
August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
The American Journal of Medicine
|
February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?
Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2024
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Christopher J Sweeney, Russell Petry, Chang Xu, et al.
Page
of 77
Search research articles
Search
Showing results (641-650 of 762) with videos related to
Sort By:
Page
of 77
Annals of Surgical Oncology
|
June 29, 2007
Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit
Katrina H Moore, Karl J Sweeney, Meaghan E Wilson, et al.
The Lancet. Oncology
|
January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Claire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
BJU International
|
April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancer
Kathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 25, 2005
Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13
Mark C Noe, Vijayalakshmi Natarajan, Sheri L Snow, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 3, 2003
Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors
Michael A Letavic, John T Barberia, Thomas J Carty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
Lauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
The Journal of Urology
|
July 27, 2011
Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer
Peter Chang, Konrad M Szymanski, Rodney L Dunn, et al.
The New England Journal of Medicine
|
August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
The American Journal of Medicine
|
February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?
Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2024
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Christopher J Sweeney, Russell Petry, Chang Xu, et al.
Page
of 77